Concepedia

ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR

Zhi‐Yi Shao, Yibo Li, Wenjie Dai, Hui Jia, Yingshi Zhang, Qiyu Jiang, Yantao Chai, Xiaojuan Li, Huiwei Sun, Ruichuang Yang,

Pharmacological Research · 2018 · 85 citations · 70 references

DOI

Concepts

References

70

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

, , +12

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +11

Sorafenib in Advanced Hepatocellular Carcinoma

재연 정 · 2008 · 5.6K citations

, , +12

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

, , +8

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2014 · 577 citations · Full text

, , +12